Information Provided By:
Fly News Breaks for May 8, 2015
MDVN
May 8, 2015 | 07:15 EDT
UBS raised its price target on Medivation to $142 from $130 following its Q1 results. The firm noted the company missed on Xtandi sales, but said they remain encouraged by the results, citing underlying demand growth, headway made in the urology segment, and the stock morphing into a pipeline story. UBS reiterated its Buy rating on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.